The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC).
Ravinder Clayton
Research Funding - Janssen Pharmaceutical ; Janssen Pharmaceuticals
Daniel Yick Chin Heng
Honoraria - Janssen Pharmaceutical ; Johnson & Johnson
Jackson S.Y. Wu
No relevant relationships to disclose
Rob Zielinski
No relevant relationships to disclose
Scott A. North
Honoraria - Janssen Pharmaceutical ; Johnson & Johnson
Urban Emmenegger
No relevant relationships to disclose
Sebastien J. Hotte
No relevant relationships to disclose
Humaid Obaid Al-Shamsi
No relevant relationships to disclose
Leo Chen
No relevant relationships to disclose
Bernhard J. Eigl
Honoraria - Janssen Pharmaceutical ; Janssen Pharmaceutical
Research Funding - Janssen Pharmaceutical